Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan

Modern Rheumatology

Volumn 26, Issue 5, 2016, Pages 667-671

  Nakajima, Ken ^a,b,c   Watanabe, Omi ^a,b   Mochizuki, Mayumi ^c   Nakasone, Ayako ^d   Ishizuka, Nobuhiko ^d   Murashima, Atsuko ^a,b  

^a Japan Drug Information Institute in Pregnancy   (Japan)

^b NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Abortions; Pregnancy outcome; Rheumatoid arthritis; Tocilizumab

Indexed keywords

LEFLUNOMIDE; METHOTREXATE; TOCILIZUMAB; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CAUDAL REGRESSION SYNDROME; DRUG WITHDRAWAL; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; INTRAUTERINE GROWTH RETARDATION; LIVE BIRTH; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; NEWBORN HYPOXIA; OUTCOME ASSESSMENT; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL EXPOSURE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPONTANEOUS ABORTION; ABNORMALITIES, DRUG-INDUCED; ABORTION, SPONTANEOUS; CHEMICALLY INDUCED; INCIDENCE; JAPAN; MALE; MATERNAL EXPOSURE; NEWBORN; PREGNANCY; RISK ASSESSMENT;

ABNORMALITIES, DRUG-INDUCED; ABORTION, SPONTANEOUS; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; INCIDENCE; INFANT, NEWBORN; JAPAN; MALE; MATERNAL EXPOSURE; PREGNANCY; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84961204382     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2016.1147405     Document Type: Article

References (39)

1. O.Sangha Epidemiology of rheumatic diseases. Rheumatology (Oxford). 2000;39(Suppl 2):3–12.
2. M.D.Lockshin Invited review:sex ratio and rheumatic disease. J Appl Physiol (1985). 2001;91:2366–73.
3. E.Myasoedova, C.S.Crowson, H.M.Kremers, T.M.Therneau, S.E.Gabriel Is the incidence of rheumatoid arthritis rising?:results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum. 2010;62:1576–82.
4. A.Golding, U.J.Haque, J.T.Giles Rheumatoid arthritis and reproduction. Rheum Dis Clin North Am. 2007;33:319–43, vi–vii.
5. M.Ostensen, P.M.Villiger The remission of rheumatoid arthritis during pregnancy. Semin Immunopathol. 2007;29:185–91.
6. Y.A.de Man, R.J.Dolhain, F.E.van de Geijn, S.P.Willemsen, J.M.Hazes Disease activity of rheumatoid arthritis during pregnancy:results from a nationwide prospective study. Arthritis Rheum. 2008;59:1241–8.
7. M.Wallenius, K.A.Salvesen, A.K.Daltveit, J.F.Skomsvoll Rheumatoid arthritis and outcomes in first and subsequent births based on data from a national birth registry. Acta Obstet Gynecol Scand. 2014;93:302–7.
8. M.Wallenius, K.A.Salvesen, A.K.Daltveit, J.F.Skomsvoll Miscarriage and stillbirth in women with rheumatoid arthritis. J Rheumatol. 2015;42:1570–2.
9. E.F.Chakravarty, D.Sanchez-Yamamoto, T.M.Bush The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age:a survey of practice patterns and pregnancy outcomes. J Rheumatol. 2003;30:241–6.
10. M.L.Krause, S.Amin, A.Makol Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis:what the rheumatologist needs to know. Ther Adv Musculoskelet Dis. 2014;6:169–84.
11. N.Umeda, S.Ito, T.Hayashi, D.Goto, I.Matsumoto, T.Sumida A patient with rheumatoid arthritis who had a normal delivery under etanercept treatment. Intern Med. 2010;49:187–9.
12. I.Natsumi, Y.Matsukawa, K.Miyagawa, H.Kodaira, T.Tanaka, A.Horikoshi, et al. Successful childbearing in two women with rheumatoid arthritis and a history of miscarriage after etanercept treatment. Rheumatol Int. 2013;33:2433–5.
13. A.Murashima, N.Watanabe, N.Ozawa, H.Saito, K.Yamaguchi Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis:drug levels in maternal serum, cord blood, breast milk and the infant’s serum. Ann Rheum Dis. 2009;68:1793–4.
14. C.Chambers, G.Koren, Z.N.Tutuncu, D.Johnson, K.L.Jones Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Organization of Teratology Information Specialists (OTIS) study. Can Fam Physician. 2007;53:409–12.
15. R.U.Hausknecht Methotrexate and misoprostol to terminate early pregnancy. N Engl J Med. 1995;333:537–40.
16. J.F.Skomsvoll, M.Wallenius, H.S.Koksvik, E.Rødevand, K.A.Salvesen, O.Spigset, et al. Drug insight:anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation. Nat Clin Pract Rheumatol. 2007;3:156–64.
17. C.H.Roux, O.Brocq, V.Breuil, C.Albert, L.Euller-Ziegler Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford). 2007;46:695–8.
18. J.Hashimoto, P.Garnero, D.van der Heijde, N.Miyasaka, K.Yamamoto, S.Kawai, et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI:data from the SAMURAI study. Mod Rheumatol. 2011;21:10–15.
19. M.C.Genovese, J.D.McKay, E.L.Nasonov, E.F.Mysler, N.A.da Silva, E.Alecock, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs:the Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy study. Arthritis Rheum. 2008;58:2968–80.
20. V.Strand, G.R.Burmester, S.Ogale, J.Devenport, A.John, P.Emery Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors:results from the 24-week randomized controlled RADIATE study. Rheumatology (Oxford). 2012;51:1860–9.
21. G.R.Burmester, A.Rubbert-Roth, A.Cantagrel, S.Hall, P.Leszczynski, D.Feldman, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis. 2014;73:69–74.
22. A.Ogata, K.Tanimura, T.Sugimoto, H.Inoue, Y.Urata, T.Matsubara, et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66:344–54.
23. Prescribing Information:Actemra (tocilizumab) 2013. Available from:http://www.gene.com/download/pdf/actemra_prescribing.pdf Accessed September 20, 2015.
24. A.Wakabayashi, K.Sawada, M.Nakayama, A.Toda, A.Kimoto, S.Mabuchi, et al. Targeting interleukin-6 receptor inhibits preterm delivery induced by inflammation. Mol Hum Reprod. 2013;19:718–26.
25. K.L.Hyrich, S.M.Verstappen Biologic therapies and pregnancy:the story so far. Rheumatology (Oxford). 2014;53:1377–85.
26. A.Calligaro, A.Hoxha, A.Ruffatti, L.Punzi Are biological drugs safe in pregnancy? Reumatismo. 2015;66:304–17.
27. T.Yamamoto Abnormal pregnancy [in Japanese]. Acta Obster Gymnaeccol Jpn. 2007;59:N663–71.
28. MedlinePlus® 2014; Miscarriage. Available from:http://www.nlm.nih.gov/medlineplus/ency/article/001488.htm Accessed November 16, 2015.
29. A.J.Wilcox, C.R.Weinberg, J.F.O’Connor, D.D.Baird, J.P.Schlatterer, R.E.Canfield, et al. Incidence of early loss of pregnancy. N Engl J Med. 1988;319:189–94.
30. A.Rubbert-Roth, P.Goupille, S.Moosavi First experiences with pregnancies n RA patients (pts) receiving tocilizumab (TCZ) therapy. Arthritis Rheum. 2010;62(Suppl 10):384.
31. Y.A.de Man, J.M.Hazes, H.van der Heide, S.P.Willemsen, C.J.de Groot, E.A.Steegers, et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight:results of a national prospective study. Arthritis Rheum. 2009;60:3196–206.
32. M.Østensen, L.Andreoli, A.Brucato, I.Cetin, C.Chambers, M.E.Clowse, et al. State of the art:reproduction and pregnancy in rheumatic diseases. Autoimmun Rev. 2015;14:376–86.
33. P.Krajewski, P.Sieroszewski, A.Karowicz-Bilinska, M.Kmiecik, A.Chudzik, B.Strzalko-Gloskowska, et al. Assessment of interleukin-6, interleukin-8 and interleukin-18 count in the serum of IUGR newborns. J Matern Fetal Neonatal Med. 2014;27:1142–5.
34. F.D.de Steenwinkel, A.C.Hokken-Koelega, Y.A.de Man, Y.B.de Rijke, M.A.de Ridder, J.M.Hazes, et al. Circulating maternal cytokines influence fetal growth in pregnant women with rheumatoid arthritis. Ann Rheum Dis. 2013;72:1995–2001.
35. K.Itabashi, F.Miura, R.Uehara, Y.Nakamura New Japanese neonatal anthropometric charts for gestational age at birth. Pediatr Int. 2014;56:702–8.
36. C.Weber-Schoendorfer, C.Chambers, E.Wacker, D.Beghin, N.Bernard, C.Network of French Pharmacovigilance, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy:a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66:1101–10.
37. R.Rai, L.Regan Recurrent miscarriage. Lancet. 2006;368:601–11.
38. M.V.Sauer Reproduction at an advanced maternal age and maternal health. Fertil Steril. 2015;103:1136–43.
39. S.M.Verstappen, Y.King, K.D.Watson, D.P.Symmons, K.L.Hyrich, BSRBR Control Centre Consortium, BSR Biologics Register. Anti-TNF therapies and pregnancy:outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70:823–6.